Systematic review finds Astragalus membranaceus compounds offer photoprotection, collagen support and even telomere benefits, but larger trials are needed
A PRISMA systematic review of studies from 2015-2025 highlights growing preclinical and emerging clinical evidence that Astragalus membranaceus and its bioactive constituents (eg, astragaloside IV, cycloastragenol, flavonoids) exert antioxidant, anti‑inflammatory and photoprotective effects relevant to skin aging. Laboratory work shows reduced oxidative stress, preserved mitochondrial function and signals for increased collagen production; intriguing data also suggest telomere‑protective effects under oxidative challenge. Small clinical trials reported improvements in hydration, tone and wrinkle appearance, but study sizes, formulations and follow‑up remain limited.
Astragalus‑containing cosmeceuticals look like an interesting adjunct for patients seeking botanical anti‑aging options, yet evidence is not yet definitive. If patients ask, discuss the plausibility of benefit, emphasize the importance of tested formulations, and continue to prioritize proven measures (photoprotection, retinoids, procedural options) while monitoring for tolerability.
Read the full review to evaluate study quality, specific extracts and dosing used, and to inform evidence‑based conversations with patients.
J Drugs Dermatol. 2026;25(1). doi:10.36849/JDD.9157
Blog write-up assisted by AI
